Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | LM-108 + Toripalimab-tpzi |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LM-108 | LM 108|LM108 | CCR8 Antibody 8 | LM-108 is a monoclonal antibody that targets CCR8 expressed on regulatory T cells and inhibits downstream signaling, potentially leading to increased antitumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr 2504), NCI Drug Dictionary). | |
Toripalimab-tpzi | Loqtorz | Toripalimab|JS001|JS-001|TAB001 | Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 119 | Loqtorz (toripalimab-tpzi) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (PMID: 28317872; PMID: 32277740, PMID: 32406293, PMID: 32321714). Loqtorz (toripalimab-tpzi) in combination with cisplatin and gemcitabine is FDA-approved for use in adult patients with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|